Skip to main content

Table 5 Biomarkers in two study groups

From: Effects of colchicine on major adverse cardiac events in next 6-month period after acute coronary syndrome occurrence; a randomized placebo-control trial

Biomarkers

Colchicine

Placebo

(n = 120)

(n = 129)

Mean ± SD, Number (%)

Correlations with MACE

P value

Mean ± SD, Number (%)

Correlations with MACE

P value

WBC

6210 ± 1357.60

0.064

0.49

6156.59 ± 1338.425

0.054

0.541

Lymphocyte

2206.67 ± 307.26

0.073

0.427

2189.92 ± 299.96

0.035

0.698

Neutrophil

3625.83 ± 857.83

0.028

0.762

3596.90 ± 834.41

0.023

0.793

Troponin

79 (65.8)

0.122

0.184

84 (65.1)

0.149

0.093

TG (mg/dl)

188.91 ± 46.46

0.106

0.249

198.34 ± 58.20

0.145

0.101

Cholesterol (mg/dl)

197.93 ± 58.73

0.063

0.496

188.76 ± 53.368

0.113

0.204

LDL-c (mg/dl)

146.43 ± 28.92

0.081

0.379

150.44 ± 27.98

0.132

0.137

HDL-c (mg/dl)

40.42 ± 5.58

0.074

0.42

39.09 ± 5.35

0.169

0.056

BUN (mg/dl)

20.23 ± 6.02

0.168

0.067

20.59 ± 4.97

0.153

0.084

Cr (mg/dl)

1.16 ± 0.21

0.166

0.07

1.13 ± 0.21

0.111

0.21

SGOT (mg/dl)

29.45 ± 6.05

0.131

0.153

30.31 ± 5.94

0.025

0.781

SGPT (mg/dl)

29.04 ± 4.85

0.145

0.114

28.45 ± 4.94

0.115

0.196

ALP (mg/dl)

174.55 ± 41.53

0.121

0.19

180.29 ± 44.26

0.048

0.589

EF (%)

49.79 ± 2.78

0.019

0.834

50.30 ± 2.68

0.146

0.099

  1. WBC, white blood cell; TG, triglycerides; LDL-c, low density lipoprotein cholesterol; HDL-c, high density lipoprotein cholesterol; Cr, creatinine; SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamic pyruvate transaminase; ALP, alkaline phosphatase; EF, ejection fraction